DANBURY, CT, March 23, 2026 /24-7PressRelease/ -- Miranda L. Carpenter has been selected for inclusion in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

Currently serving as a Scientist III with the pharmaceutical manufacturer Boehringer Ingelheim Pharmaceuticals, Ms. Carpenter has established herself as a leading expert in immuno-oncology. In her role since 2016, she proposes research targets, designs bispecific molecules — large proteins engineered for therapeutic purposes — and implements strategic plans to advance drug discovery. Her responsibilities include testing the feasibility of novel molecules to assess their efficacy and receptor binding, and evaluating downstream cell signaling pathways.

Among Ms. Carpenter's most significant achievements to date is her work on a bispecific molecule that progressed from concept to clinical trials. Over the course of four years, she conducted feasibility studies, cytotoxicity assays and experimental control design, which culminated in an investigational new drug filing with the United States Food and Drug Administration (FDA) and the initiation of first-in-human clinical trials in 2021. The antibody she developed links T cells to fibroblasts, modulating the immune system for tumor treatment — a milestone that stands as a testament to her expertise and dedication.

Ms. Carpenter's tenure at Boehringer Ingelheim has been marked by multiple recognitions for excellence, including the Achievement Award for the Milestone in Startup Development in 2022. Further establishing her standing within the scientific community, she is an active member of the Society of Toxicology and has contributed numerous publications to her field.

Prior to joining Boehringer Ingelheim, Ms. Carpenter began her career at the biotechnology firm Gen-Probe (now Hologic Immucor) in Stamford, Connecticut, in 2011. Specializing in antibody-DNA test kits for transplant diagnostics, she worked in a matrix research and development environment immediately after finishing graduate school. Her role involved Good Laboratory Practice lab work as well as Good Manufacturing Practice quality control, contributing to investigational new drug filings with the FDA.

During this time, Ms. Carpenter was responsible for designing components for LIFECODES HLA SSO typing kits, which focus on primers and probes used to assess Major Histocompatibility Complex Class I and Class II phenotypes for organ acceptance or rejection.

Hailing from an equally accomplished academic background, Ms. Carpenter earned a Master of Public Health in Environmental Health Science from New York Medical College in 2010 and completed three years of doctoral coursework in biochemistry and molecular biology. Although she left the doctoral program due to funding constraints, she gained a wealth of valuable knowledge that continues to inform her work today.

Inspired by Dr. Diane Heck's presentation on chemical warfare and carcinogenesis during an open house at New York Medical College, Ms. Carpenter enrolled in the program and was awarded a United States Department of Defense project scholarship in collaboration with Rutgers University under Dr. Heck's mentorship. Her research, which focused on developing countermeasures against chemical threats, saw her studying protease inhibitors and matrix metalloproteinases (MMP) isoforms on desiccant injury by using compounds such as nitrogen mustard and sulfur mustard. In recognition of her academic excellence, she was honored as the Distinguished Student of the Year at New York Medical College.

Before embarking on her scientific career, Ms. Carpenter worked as a funeral director after graduating from the American Academy McAllister Institute of Funeral Service in New York City around September 11, 2001. Motivated by a desire to restore dignity and driven by a longstanding fascination with anatomy and model-making, she applied these interests early on through her certification as a licensed funeral director.

Throughout her career, Ms. Carpenter has demonstrated her commitment to advancing patient care through innovative cancer research. She attributes her success to this passion as well as the inspiration she draws from ongoing advancements in oncology. Recognizing the transformative potential of artificial intelligence — particularly as utilized by interns for data analysis — she continues to seek ways to improve interpretations of the tumor microenvironment.

Beyond her professional responsibilities, Ms. Carpenter volunteers with STEM programs to inspire future generations of scientists and remains actively engaged with civic-minded organizations. In her personal life, she pursues creative endeavors such as building dollhouses and is an avid miniature enthusiast.

Looking toward the future, Ms. Carpenter aims to deepen her expertise in immuno-oncology with a focus on breakthroughs in cancer research and therapeutics while advancing personalized medicine through highly strategic initiatives designed to maximize impact within the field. Her outstanding accomplishments and future goals alike reflect her lifelong commitment to scientific research, continuous learning and desire to benefit future generations through everything she does.

About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.

# # #